Loading...
•
Mar 31, 2024
ResMed Q3 2024 Earnings Report
ResMed's Q3 2024 results reflected strong demand and operational efficiencies, leading to increased profitability.
Key Takeaways
ResMed reported a 7% increase in revenue to $1.2 billion, a 25% increase in operating profit, and a 29% increase in net income. Diluted earnings per share were $2.04, and non-GAAP diluted earnings per share were $2.13.
Revenue increased by 7% year-over-year to $1.2 billion.
Gross margin grew 260 bps to 57.9%.
Income from operations increased 25%.
Diluted earnings per share reached $2.04; non-GAAP diluted earnings per share was $2.13.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The document does not contain explicit forward guidance. Therefore, a summary and related bullet points cannot be provided.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...